Unknown PHASE3 INTERVENTIONAL 3-arm NCT01930773

Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST) (ONSIDE TEST)

Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.

Sponsor: Medical University of Warsaw

Conditions Stable Angina

Interventions Genotyping Phenotyping

Updated 7 times since 2017 Last updated: Dec 21, 2018 Started: Mar 31, 2013 Primary completion: Mar 31, 2019 Completion: Sep 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Stable Angina and is currently ongoing. Medical University of Warsaw leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2019 — Jan 2021 [monthly]

Recruiting PHASE3
Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE3

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE3

Status: Unknown Status → Recruiting
Jan 2017 — Feb 2018 [monthly]

Unknown Status PHASE3

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Warsaw
Polish Cardiac Society
University of Pecs

Data source: Medical University of Warsaw

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Balatonfüred, Hungary
• Warsaw, Poland